Microdosing Claims: Productivity, Creativity, Mood and Cognition

How this page works

Four claims come up again and again: that microdosing makes people more productive, more creative, happier and sharper. Each is checked below against the research we could read. Evidence labels: mixed (studies disagree), insufficient evidence (too little good research), no good evidence of benefit (controlled studies mostly show no advantage over placebo), and Proper evidence not found (we looked and found no usable study). No amounts or schedules appear here. For the overall picture see Human Microdosing Research.

Claim 1: Productivity

NIDA reports that people say they microdose to improve productivity, among other aims. [1] We searched the medical literature on October 22, 2026 for controlled studies measuring work performance or output in microdosers and did not find any. Proper evidence not found. The nearest evidence is on attention and cognitive tasks (see Claim 4), which are not the same as real-world productivity.

Claim 2: Creativity

• Pooling three double-blind, placebo-controlled trials of psilocybin truffles (171 people), researchers found a higher ratio of original responses on one divergent-thinking measure, but only when relative dose was considered, and no effect on other divergent or convergent thinking scores. [2]
• A double-blind study of 34 people microdosing psilocybin mushrooms found no evidence of enhanced creativity. [3]
• Label: mixed. One narrow measure improved in one analysis; a broad improvement in creativity has not been shown.

Claim 3: Mood, depression, anxiety and ADHD

• Healthy adults. A 2026 meta-analysis found no consistent immediate benefits for depressive, anxiety or stress symptoms, and called the randomized evidence inconclusive. [4] A preregistered psilocybin study found no difference from placebo on emotion processing or symptoms of anxiety and depression. [5]
• Depression. An open-label LSD study with 19 adults had no placebo group and was limited by its small size. [6] A placebo-controlled psilocybin microdosing trial in major depression has been registered, but a protocol is a plan, not a finding. [7] Label: insufficient evidence.
• ADHD. A randomized, double-blind, placebo-controlled trial randomized 53 adults with ADHD to repeated low-dose LSD or placebo. Both groups improved, with no difference between them. The LSD was safe in the outpatient setting but not more effective than placebo. [8] Label: no good evidence of benefit for ADHD from this trial.
• Why surveys look better. Large surveys find lower depression and anxiety among microdosers with mental health concerns, but the groups were self-selected. [9] See Self-Selection and Survey Limitations.

Claim 4: Cognition and focus

• An umbrella review found that current evidence does not support cognitive enhancement through microdosing. Its only significant pooled finding was a small decrease in cognitive control, which runs against popular claims. [10]
• Two truffle trials found no reliable effect on cognitive or emotional functioning beyond placebo. [11]
• A mushroom study reported only a few small changes toward cognitive impairment. [3]
• Label: no good evidence of benefit.

Why individual stories feel convincing

Positive expectations predicted better well-being in a prospective study, and many improvements disappear when a placebo is used. [12] A personal story can be sincere and still not show that the substance caused the change. See Placebo and Expectancy in Microdosing.

If you are thinking about this for a health reason

People with depression, ADHD or anxiety should talk with a licensed clinician about their options. Do not stop or change any prescribed medicine on your own; talk with your prescriber. In a crisis in the US, call or text 988, or call 911. For help judging products and sources, see Evaluating Safety Claims.